Could we address the interplay between CD133, Wnt/β-Catenin, and TERT signaling pathways as a potential target for Glioblastoma therapy?

Glioblastoma multiforme (GBM) is one of the most lethal forms of primary brain tumors. Glioblastoma stem cells (GSCs) play an undeniable role in tumor development by activating multiple signaling pathways such as Wnt/β-catenin and PI3K/AKT/mTOR that facilitate brain tumor formation. CD133, a transme...

Full description

Saved in:
Bibliographic Details
Main Authors: Behrooz, Amir Barzegar, Amir Hamzah, Amir Syahir
Format: Article
Published: Frontiers Media 2021
Online Access:http://psasir.upm.edu.my/id/eprint/96552/
https://www.frontiersin.org/articles/10.3389/fonc.2021.642719/full
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Universiti Putra Malaysia
id my.upm.eprints.96552
record_format eprints
spelling my.upm.eprints.965522023-01-11T08:45:21Z http://psasir.upm.edu.my/id/eprint/96552/ Could we address the interplay between CD133, Wnt/β-Catenin, and TERT signaling pathways as a potential target for Glioblastoma therapy? Behrooz, Amir Barzegar Amir Hamzah, Amir Syahir Glioblastoma multiforme (GBM) is one of the most lethal forms of primary brain tumors. Glioblastoma stem cells (GSCs) play an undeniable role in tumor development by activating multiple signaling pathways such as Wnt/β-catenin and PI3K/AKT/mTOR that facilitate brain tumor formation. CD133, a transmembrane glycoprotein, has been used to classify cancer stem cells (CSCs) in GBM. The therapeutic value of CD133 is a biomarker of the CSC in multiple cancers. It also leads to growth and recurrence of the tumor. More recent findings have confirmed the association of telomerase/TERT with Wnt/β-catenin and the PI3K/AKT/mTOR signaling pathways. Advance studies have shown that crosstalk between CD133, Wnt/β-catenin, and telomerase/TERT can facilitate GBM stemness and lead to therapeutic resistance. Mechanistic insight into signaling mechanisms downstream of surface biomarkers has been revolutionized by facilitating targeting of tumor-specific molecular deregulation. This review also addresses the importance of interplay between CD133, Wnt/β-catenin and TERT signaling pathways in GSCs and outlines the future therapeutic goals for glioblastoma treatment. Frontiers Media 2021 Article PeerReviewed Behrooz, Amir Barzegar and Amir Hamzah, Amir Syahir (2021) Could we address the interplay between CD133, Wnt/β-Catenin, and TERT signaling pathways as a potential target for Glioblastoma therapy? Frontiers in Oncology, 11. art. no. 642719. pp. 1-9. ISSN 2234-943X https://www.frontiersin.org/articles/10.3389/fonc.2021.642719/full 10.3389/fonc.2021.642719
institution Universiti Putra Malaysia
building UPM Library
collection Institutional Repository
continent Asia
country Malaysia
content_provider Universiti Putra Malaysia
content_source UPM Institutional Repository
url_provider http://psasir.upm.edu.my/
description Glioblastoma multiforme (GBM) is one of the most lethal forms of primary brain tumors. Glioblastoma stem cells (GSCs) play an undeniable role in tumor development by activating multiple signaling pathways such as Wnt/β-catenin and PI3K/AKT/mTOR that facilitate brain tumor formation. CD133, a transmembrane glycoprotein, has been used to classify cancer stem cells (CSCs) in GBM. The therapeutic value of CD133 is a biomarker of the CSC in multiple cancers. It also leads to growth and recurrence of the tumor. More recent findings have confirmed the association of telomerase/TERT with Wnt/β-catenin and the PI3K/AKT/mTOR signaling pathways. Advance studies have shown that crosstalk between CD133, Wnt/β-catenin, and telomerase/TERT can facilitate GBM stemness and lead to therapeutic resistance. Mechanistic insight into signaling mechanisms downstream of surface biomarkers has been revolutionized by facilitating targeting of tumor-specific molecular deregulation. This review also addresses the importance of interplay between CD133, Wnt/β-catenin and TERT signaling pathways in GSCs and outlines the future therapeutic goals for glioblastoma treatment.
format Article
author Behrooz, Amir Barzegar
Amir Hamzah, Amir Syahir
spellingShingle Behrooz, Amir Barzegar
Amir Hamzah, Amir Syahir
Could we address the interplay between CD133, Wnt/β-Catenin, and TERT signaling pathways as a potential target for Glioblastoma therapy?
author_facet Behrooz, Amir Barzegar
Amir Hamzah, Amir Syahir
author_sort Behrooz, Amir Barzegar
title Could we address the interplay between CD133, Wnt/β-Catenin, and TERT signaling pathways as a potential target for Glioblastoma therapy?
title_short Could we address the interplay between CD133, Wnt/β-Catenin, and TERT signaling pathways as a potential target for Glioblastoma therapy?
title_full Could we address the interplay between CD133, Wnt/β-Catenin, and TERT signaling pathways as a potential target for Glioblastoma therapy?
title_fullStr Could we address the interplay between CD133, Wnt/β-Catenin, and TERT signaling pathways as a potential target for Glioblastoma therapy?
title_full_unstemmed Could we address the interplay between CD133, Wnt/β-Catenin, and TERT signaling pathways as a potential target for Glioblastoma therapy?
title_sort could we address the interplay between cd133, wnt/β-catenin, and tert signaling pathways as a potential target for glioblastoma therapy?
publisher Frontiers Media
publishDate 2021
url http://psasir.upm.edu.my/id/eprint/96552/
https://www.frontiersin.org/articles/10.3389/fonc.2021.642719/full
_version_ 1755873913006456832